TGN 167

Drug Profile

TGN 167

Alternative Names: TGN-167

Latest Information Update: 15 Apr 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Trigen Holdings AG
  • Class Anticoagulants; Antithrombotics
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 21 Feb 2008 No development reported - Phase-I for Thrombosis in United Kingdom (PO)
  • 31 May 2005 ProCorde GmbH has merged with Trigen Holdings plc to form Trigen Holdings AG
  • 24 Nov 2004 Trigen and Eurand have entered into an agreement to co-develop controlled-release formulations of TGN 167
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top